var data={"title":"Pegaspargase: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pegaspargase: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6730?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pegaspargase-drug-information\" class=\"drug drug_general\">see &quot;Pegaspargase: Drug information&quot;</a> and <a href=\"topic.htm?path=pegaspargase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pegaspargase: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206778\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Oncaspar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50616077\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Oncaspar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049174\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Enzyme</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26965157\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=pegaspargase-drug-information\" class=\"drug drug_general\">see &quot;Pegaspargase: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">(Refer to individual protocols): Children &gt;1 year, Adolescents, and  Adults: IM, IV: 2,500 units/m<sup>2</sup>/dose &ge; every 14 days (as part of a combination chemotherapy regimen)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206757\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oncaspar: 750 units/mL (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206742\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049178\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Limit the volume at a single injection site to 2 mL; for IM administration, if the volume to be administered is &gt;2 mL, use multiple injection sites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Administer dose as an IV infusion over a period of 1 to 2 hours through a running IV infusion line. Use of a 0.2 micron filter may result in some loss of potency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206773\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Do not shake; protect from light. Discard vial if previously frozen, stored at room temperature for &gt;48 hours, excessively shaken/agitated, or if cloudy, discolored, or if precipitate is present. If not used immediately, solutions diluted for infusion in NS or D5W should be protected from light, refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) and used within 48 hours (including administration time).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049177\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">First-line treatment of newly diagnosed acute lymphoblastic leukemia (ALL) as part of a multiple chemotherapeutic drug regimen (FDA approved in ages &ge;1 year and adults); induction treatment of acute lymphoblastic leukemia in combination with other chemotherapeutic agents in patients who have developed hypersensitivity to native forms of L-asparaginase derived from <i>E. coli</i> and/or <i>Erwinia chrysanthemia</i> (FDA approved in ages &ge;1 year and adults); has been used for the treatment of lymphoma and acute myelogenous leukemia (AML)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206808\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oncaspar may be confused with Elspar</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pegaspargase may be confused with asparaginase (<i>E. coli</i>), asparaginase (<i>Erwinia</i>), peginesatide</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3136296\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Thrombosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Cerebral thrombosis (or hemorrhage of the brain)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperglycemia (some patients required insulin therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Pancreatitis (includes 3 deaths)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic: Blood coagulation disorder (includes increased prothrombin time or partial thromboplastin time or decreased serum fibrogen)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, hyperbilirubinemia, increased serum transaminases (ALT, AST)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction (includes anaphylaxis, bronchospasm, erythema, hives, hypotension, laryngeal edema, skin rash, swelling, urticaria; relapsed ALL with no prior asparaginase hypersensitivity, relapsed ALL with prior asparaginase hypersensitivity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Hypersensitivity to L-asparaginase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal pain, anemia, arthralgia, bronchospasm, chest pain, coagulation time increased, colitis, confusion, constipation, deep vein thrombosis, disseminated intravascular coagulation, dizziness, dyspnea, emotional lability, endocarditis, facial edema, gastrointestinal pain, headache, hemorrhagic cystitis, hepatic failure, hyperuricemia, hypoglycemia, increased thirst, lip edema, liver steatosis, myalgia, night sweats, ostealgia, pancytopenia, paresthesia, purpura, renal failure, sagittal sinus thrombosis, seizure, septic shock, superficial venous thrombosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206763\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">History of serious allergic reactions to pegaspargase or any component of the formulation; history of any of the following with prior L-asparaginase treatment: serious thrombosis, pancreatitis, and/or serious hemorrhagic events</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe hepatic impairment (bilirubin &gt;3 times upper limit of normal [ULN]; transaminases &gt;10 times ULN).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206746\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergic reactions: Anaphylaxis and serious allergic reactions (eg, bronchospasm, hypotension, laryngeal edema, local erythema or swelling, systemic rash, urticaria) may occur; discontinue in patients with serious allergic reaction. The risk of serious allergic reactions is increased in patients with a history of hypersensitivity reactions to other L-asparaginase products. Observe patients for 1 hour after administration; equipment and immediate treatment for hypersensitivity reactions should be available during administration.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Coagulopathy: Increased prothrombin time, increased partial thromboplastin time, and hypofibrinogenemia may occur. Severe or symptomatic coagulopathy may require treatment with fresh-frozen plasma. Use cautiously in patients with an underlying coagulopathy or previous hematologic complications from asparaginase. Monitor coagulation parameters at baseline and periodically during and after therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Glucose intolerance: May cause glucose intolerance; irreversible in some cases. Use with caution in patients with diabetes mellitus and hyperglycemia. Monitor serum glucose. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: Altered liver function tests (eg, increased AST, ALT, alkaline phosphatase, bilirubin [direct and indirect], and decreased serum albumin, plasma fibrinogen) may occur with therapy. Use with caution in patients with pre-existing hepatic impairment. Monitor liver function tests at baseline and periodically during treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pancreatitis: May occur; promptly evaluate patients with abdominal pain. The manufacturer recommends discontinuing pegaspargase  if pancreatitis occurs during treatment. May consider continuing therapy for asymptomatic chemical pancreatitis (amylase or lipase &gt;3 times ULN) or only radiologic abnormalities; monitor closely for rising amylase and/or lipase levels (Stock 2011). Discontinue permanently for clinical pancreatitis (eg, vomiting, severe abdominal pain) with amylase/lipase elevation &gt;3 times ULN for &gt;3 days and/or development of a pancreatic pseudocyst. Avoid alcohol use (Stock 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thrombotic events: Serious thrombotic events, including sagittal sinus thrombosis may occur; discontinue with serious thrombotic event. Anticoagulation prophylaxis during therapy may be considered in some patients (Farge 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;\t Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration route: In a study comparing IV pegaspargase to IM native <i>E. coli</i> asparaginase for post-induction treatment in children with ALL, 5-year disease-free survival did not differ and the overall frequency of asparaginase-related toxicities (including allergy, pancreatitis, and thrombotic or bleeding complications) did not differ between the IV pegaspargase and IM native <i>E. coli</i> apsaraginase groups. The median nadir serum asparaginase activity was significantly higher in the IV pegaspargase group. Reported treatment-related anxiety was significantly lower (for both patients and guardians) in the group that received IV pegaspargase (Place 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Medication error prevention: Do not interchange pegaspargase for asparaginase (<i>E. coli</i>) or asparaginase (<i>Erwinia</i>); ensure the proper asparaginase formulation, route of administration, and dose prior to administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299829\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222178\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12682&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegloticase: May diminish the therapeutic effect of Pegaspargase.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206753\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206766\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with pegaspargase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049173\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs during administration, CBC with differential, platelet count, urinalysis, serum amylase, liver enzymes, bilirubin, prothrombin time, renal function tests, urine glucose, blood glucose, uric acid, fibrinogen levels. Observe patients for 1 hour after administration for signs of anaphylaxis and serious allergic reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206745\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pegaspargase is a modified version of L-asparaginase, conjugated with polyethylene glycol. In leukemic cells, asparaginase hydrolyzes L-asparagine to ammonia and L-aspartic acid, leading to depletion of asparagine. Leukemia cells, especially lymphoblasts, require exogenous asparagine; normal cells can synthesize asparagine. Asparagine depletion in leukemic cells leads to inhibition of protein synthesis and apoptosis. Asparaginase is cycle-specific for the G<sub>1</sub> phase of the cell cycle. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206762\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset: Asparagine depletion: IM: Within 4 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Asparagine depletion: IV (in asparaginase naive adults): 2 to 4 weeks (Douer 2007); IM: ~21 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Not absorbed from the GI tract; therefore, requires parenteral administration; IM: Slow</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Apparent V<sub>d</sub>: Plasma volume: IM: Children: 1.5 L/m<sup>2</sup>; IV: Adults (asparaginase naive): 2.4 L/m<sup>2 </sup> (Douer 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Systemically degraded </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Children: 5.8 days; Adults: 5.5-6 days; 3.2 &plusmn; 1.8 days in patients who previously had a hypersensitivity reaction to native L-asparaginase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Adults (asparaginase naive): 7 days (Douer 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: IM: 3 to 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Clearance is unaffected by age, renal function, or hepatic function; not detected in urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323630\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Oncaspar Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">750 units/mL (5 mL): $17,453.45</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038720\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ai Yang (CN);</li>\n      <li>Oncaspar (BB, CZ, IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Asselin BL, Whitin JC, Cappola DJ, et al, &ldquo;Comparative Pharmacokinetic Studies of Three Asparaginase Preparations,&rdquo; <i>J Clin Oncol</i>, 1993, 11(9):1780-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-pediatric-drug-information/abstract-text/8355045/pubmed\" target=\"_blank\" id=\"8355045\">8355045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avramis VI and Panosyan EH, &quot;Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations: The Past, the Present and Recommendations for the Future,&quot; <i>Clin Pharmacokinet</i>, 2005, 44(4):367-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-pediatric-drug-information/abstract-text/15828851/pubmed\" target=\"_blank\" id=\"15828851\">15828851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avramis VI and Spence SA, &quot;Clinical Pharmacology of Asparaginases in the United States: Asparaginase Population Pharmacokinetic and Pharmacodynamic (PK-PD) Models (NONMEM) in Adult and Pediatric ALL Patients,&quot; <i>J Pediatr Hematol Oncol</i>, 2007, 29(4):239-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-pediatric-drug-information/abstract-text/17414566/pubmed\" target=\"_blank\" id=\"17414566\">17414566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avramis VI, Sencer S, Periclou AP, et al, &quot;A Randomized Comparison of Native <i>Escherichia coli</i> Asparaginase and Polyethylene Glycol Conjugated Asparaginase for Treatment of Children With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia: A Children's Cancer Group Study,&quot; <i>Blood</i>, 2002, 99(6):1986-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-pediatric-drug-information/abstract-text/11877270/pubmed\" target=\"_blank\" id=\"11877270\">11877270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capizzi RL, &ldquo;Asparaginase Revisited,&rdquo; <i>Leuk Lymphoma</i>, 1993, 10(Suppl):147-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-pediatric-drug-information/abstract-text/8481663 /pubmed\" target=\"_blank\" id=\"8481663 \">8481663 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douer D, Yampolsky H, Cohen LJ, et al, &quot;Pharmacodynamics and Safety of Intravenous Pegaspargase During Remission Induction in Adults Aged 55 Years or Younger With Newly Diagnosed Acute Lymphoblastic Leukemia,&quot; <i>Blood</i>, 2007, 109(7):2744-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-pediatric-drug-information/abstract-text/17132721/pubmed\" target=\"_blank\" id=\"17132721\">17132721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>J Thromb Haemost</i>. 2013;11(1):56-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-pediatric-drug-information/abstract-text/23217107/pubmed\" target=\"_blank\" id=\"23217107\">23217107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jarrar M, Gaynon PS, Periclou AP, et al, &quot;Asparagine Depletion After Pegylated <i>E. coli</i> Asparaginase Treatment and Induction Outcome in Children With Acute Lymphoblastic Leukemia in First Bone Marrow Relapse: A Children's Oncology Group Study (CCG-1941),&quot; <i>Pediatr Blood Cancer</i>, 2006, 47(2):141-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-pediatric-drug-information/abstract-text/16425271/pubmed\" target=\"_blank\" id=\"16425271\">16425271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. <i>Leuk Lymphoma</i>. 2011;52(12):2237-2253.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegaspargase-pediatric-drug-information/abstract-text/21827361/pubmed\" target=\"_blank\" id=\"21827361\">21827361</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12682 Version 107.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F206778\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50616077\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1049174\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F26965157\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F206757\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F206742\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1049178\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F206773\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1049177\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F206808\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3136296\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F206763\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F206746\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299829\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222178\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F206753\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F206766\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1049173\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F206745\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F206762\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323630\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038720\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12682|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pegaspargase-drug-information\" class=\"drug drug_general\">Pegaspargase: Drug information</a></li><li><a href=\"topic.htm?path=pegaspargase-patient-drug-information\" class=\"drug drug_patient\">Pegaspargase: Patient drug information</a></li></ul></div></div>","javascript":null}